Finally and as the initial descriptions of STIM1PM were related to the control of cell survival [27, 28], we next decided to test the neutralizing capacity of the anti-STIM1 mAb clone GOK to control B-CLL cell survival (STIM1PM high n = 9; and STIM1PM low n = 8) when used alone or in combination with RTX, an anti-CD20 mAb (Fig. 6b). Here, STIM1 is linked to B-cell chronic lymphocytic leukemia.